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ANALYSIS OF THE DIRECT COST GENERATED 
BY INFLIXIMAB TO NORMALIZE QUALITY OF 
LIFE IN PATIENTS WITH CROHN’S DISEASE
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Quataert M4, Goossens A4, Rutgeerts P2
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Brussels, Belgium
OBJECTIVES: Infliximab (I) 5mg/kg is effective to con-
trol refractory Crohn’s disease in 81% and to improve
fistulas in 68% of patients, thus greatly improving qual-
ity of life (QoL). The objective of this study was to calcu-
late the direct costs generated by I to achieve this im-
provement of QoL in patients responding to therapy.
METHODS: This mirror-image study was carried out in
35 patients, 19 with refractory disease and 16 with fistu-
las, responding to therapy. All patients were followed at
the same institution solely for at least six months prior
and six months after I. All direct costs to the Belgian pub-
lic payer were recorded for every 6-month time period
before and after I. The cost of I was calculated separately.
IBDQ scores were recorded before and after I for each
period. RESULTS: There was an important build up of
costs in each period (2 1.5y: 814 Euro; 1.5 1.0y:
1,408 Euro; 1.0 0.5: 2,250 Euro) culminating in a
cost of care of 2,456 Euro in the six months prior to I as
a result of the refractoriness of the disease. After I there
was a sharp decrease of the cost of care (excluding the
cost of I) to 2,024 Euro (0 0.5y) and 1,304 Euro (0.5
1.0y). The average cost of I in the first six months was
5,037 Euro and in the second six months 902 Euro. The
IBDQ increased from 147.8 (SE 8.4) to 187.8 (SE 7.0).
The total direct cost of care after I, adjusted for the re-
sponse rate, was calculated to be 16 Euro per day of nor-
malized QoL. CONCLUSIONS: Although the cost of in-
fliximab is substantial, the total direct cost to produce a
normal QoL in the entire year after therapy is quite ac-
ceptable, providing that patients not responding are not
further treated.
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EVALUATION OF THE DIRECT COST OF CARE 
FOR PATIENTS SUFFERING
FROM HEMORRHOIDS
Taïeb C, Smadja C
Pharmaco-Economic programs, Pierre Fabre SA Laboratories, 
Boulogne, France
CONTEXT: Victims due to the uneasiness, which is
caused by their socially shameful nature with persons
who suffer, haemorrhoids seem to be neglected by the
scientific community. There are lacks in the literature
concerning the health epidemiology and economy. Its
high prevalance and its invalidating aspect make that this
venous affection is a real health problem for public health
in the Western Countries: A prevalence of 4.4% is re-
ported. OBJECTIVE: Evaluating following a society per-
spective the cost of care for patients suffering from haem-
orrhoids. METHODOLOGY: Data presented come from
different bases (Medline, Pascal, Ohe-ifpma) as well as from
the SESI survey concerning pathologies treated in hospital
services for short duration as well as PMSI 2000. RESULTS:
American patients with mid or moderate haemorrhoids
have in average per year of: 1.25 medical consultations,
0.8 prescriptions and 1.38 medical/surgery procedures.
About 63.9% of patients are treated without drug. Sur-
gery seems to be done on 1.37% of the outpatients. 72%
of the financial cost of haemorrhoids seems to be due to
hospitalization for surgery. Following the SESI (last
available data, 1993), the number of estimated short hos-
pital stays for haemorrhoids is 51.400, which represents
0.4% of all annual French hospital short stays. 87.3% of
the stays are due to surgery. The average stay is 5.7 days;
the cost of stay can be estimated (data PMSI, 2000) to al-
most 1685 euros. CONCLUSION: The population suf-
fering from haemorrhoids is important and the financial
impact for the community is far from being negligible. By
extrapolation we have estimated the cost of care at 138
Millions Euros out of which 92 Millions of Euros are for
hospitalization only. This evaluation does not take into
consideration indirect cost or cost for self-medication.
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OBJECTIVE: With a prevalence up to 20%, IBS is one of
the most common diseases in the western world. IBS is
characterized by a combination of persistent and recur-
rent abdominal pain and abnormal bowel habits (diar-
rhea, constipation or both). IBS is said to be the second
most common cause of work absenteeism. Nevertheless,
the economic burden of IBS is often underestimated. This
study is the first one in Germany showing the burden of
mixed and constipation-type IBS. METHODS: The data
from 200 patient records were documented by physicians’
interviews. 100 patients were interviewed directly. Re-
source use in the past 12 months (physicians’ data) and 6
months (patients’ data) as well as quality of life data were
documented. RESULTS: The average annual societal
costs of IBS were DM 2,300 per patient. Of this, DM
1,729 was paid by the social sickness funds. Costs in-
creased with severity of disease, defined by subjects glo-
bal assessment (SGA), from DM 1,874 (mild) to DM
3,386 (severe/very severe) from the societal perspective
and from DM 1,552 to DM 2,703 from the health insur-
ance’s perspective. Cost drivers were drug expenditures
(33%), inability to work (21%) and outpatient treatment
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(20%). Quality of life, documented with a generic (EQ-
5D) and a disease-specific questionnaire (IBSQOL), showed
that patients are severely affected by IBS. The EQ-5D tar-
iff was decreased to 0.63. The IBSQOL showed that peo-
ple have strong discomfort in daily activities, and mood
and food intake are affected. CONCLUSION: It is obvi-
ous that a reduction in severity of disease will reduce so-
cietal as well as social sickness fund costs. In further re-
search, we will use data to model estimated cost savings
obtained through the introduction of new therapeutic op-
tions with increased effectiveness.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. Gastroparesis refers to ab-
normal gastric emptying, encompassing a variety of up-
per gastrointestinal symptoms that are difficult to quantify.
The purpose of this study is to describe the development
and initial testing of a new self-report measure, the Pa-
tient Assessment of Upper GastroIntestinal Disorders-
Symptom Severity Index (PAGI-SYM) in subjects with
gastroparesis. METHODS & RESULTS: Instrument
content was based on a review of the published literature
and patient and clinician interviews. The 37-item PAGI-
SYM is comprised of six subscales: heartburn, reflux/re-
gurgitation, nausea/vomiting, abdominal pain, bloating/
early satiety, and other symptoms. Psychometric evalua-
tion of the PAGI-SYM in 120 subjects with gastroparesis
identified through six clinical sites in the US is currently
being completed. Subjects complete the PAGI-SYM, the
SF-36, and a measure of patient-rated change in gastro-
paresis-related symptoms, the Overall Treatment Effect
Scale (OTE), by way of telephone interview. Two-week
reproducibility will be evaluated in 30 subjects. The
PAGI-SYM will be analyzed for internal consistency reli-
ability, reproducibility, and validity. 104 subjects have
been enrolled in the study to date. Data collection is pro-
ceeding with data analysis to be completed by October 1.
CONCLUSION: The results of this study will provide
valuable information on the psychometric properties of
the PAGI-SYM. 
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IN FINLAND, SWEDEN AND THE UK, ON 
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OBJECTIVES: In recent clinical trials, esomeprazole, a
new proton pump inhibitor, has been shown to be effec-
tive for long-term on demand treatment (medication taken
as needed) to control recurrent symptoms in patients
with Gastro-Oesophageal Reflux Disease (GORD) with-
out oesophagitis. The objective of this analysis was to
evaluate the cost-effectiveness of on demand treatment
with esomeprazole, 20 mg, compared with intermittent
treatment courses with omeprazole, 20 mg, od, or contin-
uous omeprazole treatment following relapse in patients
with GORD without oesophagitis. METHODS: A simple
Markov model was designed to compare the cost-effec-
tiveness of esomeprazole on demand treatment for six
months with a strategy comprising intermittent treatment
courses of omeprazole. In a further comparison, the strict
intermittent omeprazole strategy was replaced by a strat-
egy where continuous treatment was prescribed follow-
ing a first relapse, which better reflects conventional care.
Patient management was based on results from a UK
physician survey of patient management in clinical prac-
tice. The UK survey results were adjusted for Finland and
Sweden based on expert opinions. Direct medical costs in
Finland, Sweden and the UK were used. Time with
GORD, defined as weeks with symptoms during relapses,
was used as the measure of effectiveness. RESULTS: Time
with GORD was 0.4 weeks per patient in the esomepra-
zole on demand strategy, 2.2 weeks in the intermittent
omeprazole strategy and 1.8 weeks in the conventional
omeprazole strategy. The esomeprazole strategy incurred
lower costs than either omeprazole strategy. This analysis
represents a conservative estimate of the cost-effective-
ness of on demand treatment with esomeprazole, since
data from clinical trials using placebo plus antacids as
rescue medication were used as a substitute for relapse in
patients with GORD without oesophagitis.
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OBJECTIVES: Patients with Gastro-Oesophageal Reflux
Disease (GORD) in primary care usually receive empiri-
cal treatment based on symptoms, without referral for
endoscopy. Esomeprazole is a new proton pump inhibi-
